For 20 years, interventional cardiologists denied the need for embolic protection devices, considering embolic events to generally be the infrequent results of poor technique. Nevertheless, recent data has revealed embolization as a potentially serious and relatively common event during percutaneous coronary interventions. While embolic protection devices have been shown to dramatically reduce embolic complications, physician adoption is slow. Several companies are developing different approaches to protect against embolization, recognizing that better patient data alone isn't enough to convince interventionalists to employ these devices.
by Stephen Levin
Nowhere in medicine have clinicians and product companies more heavily bought into the value of evidence-based medicine than in interventional...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
As BD refines its commercial model, it has also brought leadership transition to its finance organization. The company recently announced that executive vice president and chief financial officer Chris DelOrefice will depart BD effective Dec. 5.
Record Mako installations in the third quarter fueled growth across Stryker’s orthopedics portfolio, supporting higher revenue in the “Ortho Other” category. Executives said new product launches and software upgrades are broadening clinical applications.
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Philips puts its latest “disappointing” warning letter into context, while announcing progress in regulatory performance, expanded US production and tariff resilience plans
An interactive look at medtech and diagnostics deals made during October 2025. Data courtesy of Biomedtracker.
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Nearly one year into leading their agencies, US FDA Commission Marty Makary and CMS Administrator Mehmet Oz took to the stage together at the Milken Institute’s Future of Health Summit 2025 to highlight what they see as progress and lay out plans for the road ahead.
